KRAS突变 英语是什么意思 - 英语翻译

• KRAS mutations
• KRAS mutation

在 中文 中使用 Kras突变 的示例及其翻译为 英语

这些研究是在没有选择Kras突变患者的情况下进行的。
Those studies were done without selecting patients for KRAS mutations.

KRAS突变也与吸烟有关。
KRAS mutations are strongly associated with tobacco smoke.

这是可能的，因为KRAS突变在其他癌症中发现。
It is possible, since KRAS mutations are found in other cancers.

KRAS突变影响癌细胞的生长和分裂。
The KRAS mutation affects how cancer cells grow and divide.

KRAS突变往往带来更大的侵袭性。
KRAS mutations often lead to greater invasiveness.

随着肿瘤KRAS突变不抗EGFR治疗的反应。
Tumors with the KRAS mutation do not respond to anti-EGFR therapy.

是否有必要重复KRAS突变试验？?
Is it necessary to repeat an ALK mutation test?

但大多数KRAS突变过于活跃，不能被神经纤维蛋白控制。
But most KRAS mutations are overly active and cannot be controlled by neurofibromin.

事实上，高达90%的胰腺癌是由KRAS突变驱动的，研究人员利用胰腺癌细胞株进行了目前的研究。
In fact, up to 90 percent of pancreatic cancers are driven by KRAS mutations, and the investigators used pancreatic cancer cell lines for the current study.

通常情况下，如果主肿瘤具有KRAS突变，所以将转移性肿瘤。
Frequently, if the primary tumor has a KRAS mutation, so will the metastatic tumor.

如果您癌组织中含有KRAS突变，那么你就不会从受益EGFR靶向治疗。
If tissue from your cancer contains a KRAS mutation, then you will not benefit from EGFR targeted therapies.

而同时阻断3条信号通路IGF1R，MAPK和PI3K/AKT/mTOR时，携带KRAS突变的癌细胞不能存活。
While blocking the three signaling pathways, IGF1R, MAPK and PI3K/AKT/mTOR, cancer cells carrying KRAS mutations could not survive.

KRAS突变检测来确定药物是否会成为治疗癌症的这些有效的这些。
KRAS mutation testing is used to determine whether these drugs will be effective in treating these cancers.

将这些抗体应用到它们的目标中，发现有5种蛋白质广泛分布在细胞系中，这是KRAS突变。
Applying the antibodies to their targets revealed that five of the proteins are broadly distributed on cell lines harboring KRAS mutations.

所需要的只是一种化合物来逆转KRAS突变的影响。
All that is required is the effect of the compound to reverse the KRAS mutation.

结肠癌的大约30％至40％和肺癌的15％至30％具有KRAS突变。
Approximately 30% to 40% of colon cancers and 15% to 30% of lung cancers have KRAS mutations.

研究人员从72名患者中的45名确定了体细胞激活KRAS突变;
The researchers identified somatic activating KRAS mutations in tissue samples from 45 of the 72 patients;

每年，英国约有2800人将患有致命的G12CKRAS突变而罹患肺癌。
Every year, around 2800 people in the UK will develop lung cancers with the deadly G12C KRAS mutation.

PIK3CA突变在这两个亚型中都被发现，而KRAS突变只在腺癌中发现。
While PIK3CA mutations appeared in both subtypes, KRAS mutations were found only in adenocarcinomas.

所需要的只是一种化合物来逆转KRAS突变的影响。
All that is needed is for a compound to reverse the effect of the KRAS mutation.

大约13%的肺腺癌、3%的结肠直肠癌和2%的其它实体瘤都包含KRAS突变。
Around 13% of lung adenocarcinomas, 3% of colorectal cancers and 2% of other solid tumours contain a mutation in KRAS.

如果您患有结肠直肠癌，那么检测KRAS突变是有帮助的。
If you have colorectal cancer, it is helpful to be tested for the KRAS mutation.

Braf突变（16%）或kras（35%）的患者相加超过半数。
Mutations in BRAF(16%) or KRAS(35%) were reported for over half of the patients.

一名患者携带两种不同的KRAS突变，c.
One patient harbored two different KRAS mutations, c.35G→T and c.

许多不同类型癌症背后的KRAS突变的影响比以前想象的更为多样.
The effects of KRAS mutations underlying many different types of cancer are more diverse than previously thought, according to a.

几乎100％的罕见粘液性癌都有KRAS突变和ERBB2扩增（也称为Her2/neu）。
Almost 100% of rare mucinous carcinomas have mutations in KRAS and amplifications of ERBB2(also known as Her2/neu).

MiratiTherapeutics正在与Amgen(NASDAQ：AMGN)竞争，以寻找一种能够成功抑制KRAS突变的药物。
Mirati Therapeutics is in a race with Amgen(NASDAQ: AMGN) to find a drug that successfully inhibits KRAS- mutations.

检测KRAS基因突变在肿瘤组织中，以引导癌症治疗，并评估预测.
To detect a KRAS gene mutation in tumor tissue in order to guide cancer therapy and to evaluate prognosis.

多达四分之一的人类癌症有KRAS基因突变，KRAS基因负责一种控制细胞生长的蛋白质。
Up to one in four human cancers have a mutation in the KRAS gene, which is responsible for a protein that controls cell growth.

PDAC的遗传分析表明，KRAS突变存在于大多数患者中，在癌症的起始、发展和转移中也起着重要作用。
PDAC genetic analyses show that KRAS mutations are encountered in a majority of patients and play a significant role in cancer initiation, progression and metastasis.